Flywire’s Q2 Earnings Call: Our Top 5 Analyst Questions

Flywire reported Q2 revenue of $163.8M, up 28.5% year over year and above analysts’ $156.7M estimate, with adjusted EBITDA of $24.04M. Adjusted EPS was $0.11. Q3 CY2026 revenue guidance midpoint is $231M. Management discussed visa-regulation assumptions, education software adoption, margin drivers, and AI cost controls.

Original reporting
Published Aug 11, 2026, 7:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 7:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Flywire’s Q2 Earnings Call: Our Top 5 Analyst Questions — source image
Decision brief

The 30-second read

$FLYWBullishMed
01

Why it matters

Traders can use the disclosed Q2 beats, Q3 revenue guidance, and management’s explicit visa-regulation assumption to update near-term expectations and risk scenarios for education demand and margin trajectory.

02

Market read

The article contains concrete earnings metrics and Q3 guidance plus management’s stated assumptions, which can drive immediate repricing of growth and margin expectations.

03

What to watch

Operating margin remains negative (-1.7%), so the market may still demand evidence of sustained profitability improvement beyond one quarter’s improvement.

Relevance 8/10Novelty 6/10Timing: pre-market today, following Flywire’s Q2 earnings call

Background

The piece summarizes Flywire’s Q2 earnings call, highlighting analyst Q&A themes around visa policy, business mix, retention, gross margin drivers, and AI-related expense control.

Company-level read

Ticker impact

$FLYWBullishMedium confidence
Context

Flywire reported Q2 revenue of $163.8M, beat estimates, and guided Q3 revenue to $231M midpoint, plus margin improvement.

Expected impact

Near-term bias higher as traders price in the Q3 revenue beat and margin trajectory, though visa-regulation assumptions add uncertainty.

Evidence & confidence

The article provides specific Q2 beats and a Q3 guidance midpoint above analyst estimates, plus management commentary that guidance assumes a 30% visa decline.

Market effects

Supports the narrative that payment workflow software and cross-sell in education and travel are scaling, potentially benefiting peers in cross-border payments software.

Visa-regulation sensitivity highlights risk to education-related demand assumptions in the US, affecting sentiment around cross-border education payments.

If visa assumptions prove wrong, it could shift expectations for international education payment volumes and software adoption timelines globally.

Counterpoint

The Q3 guidance is built on an assumed 30% visa decline, so any policy outcome worse than that could quickly reverse the positive read-through.

Key entities

  • Flywire

    US-listed payments workflow and software provider reporting Q2 results and Q3 guidance, with analyst Q&A on visa policy and margin drivers.

  • Michael Massaro

    CEO cited on differentiated software offerings, market share, and assumptions behind guidance.

  • Cosmin Pitigoi

    CFO cited on expense visibility and AI investment costs, and on gross margin economics.

Related articles

$FLYWHigh

Flywire Corp (FLYW): Results of Operations and Financial Condition

Flywire Corp (FLYW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 flyw-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Flywire Reports Second Quarter 2026 Financial Results Second Quarter Revenue Increased 27.2% Year-over-Year Second Quarter Revenue Less Ancillary Services Increased 28.5% Year-over-Year Previous Fiscal Year 2026 FX-Neutral Re

$BKSYMed

BlackSky (BKSY) Q2 2026 Earnings Call Transcript

BlackSky (BKSY) discussed its Q2 2026 earnings call, citing Gen-3 satellite performance and Spectra AI platform. It reported Q2 total revenue up 50% year over year, adjusted EBITDA margin of 14% on $33 million revenue, and $200 million year-to-date bookings. The company raised $150 million, boosting liquidity above $325 million, and said Gen-3 related products drove 90% of growth.

$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.